Long noncoding RNA LINC01510 promotes the growth of colorectal cancer cells by modulating MET expression

• Main Authors: Chaoqun Cen, Jian Li, Jingjing Liu, Mingshi Yang, Tianyi Zhang, Yu Zuo, Changwei Lin, Xiaorong Li
• Format: Article
• Language: English
• Published: BMC 2018-03-01
• Series: Cancer Cell International
• Subjects: LINC01510; Long non coding RNA; Cell cycle; Cell growth; MET; Colorectal cancer
• Online Access: http://link.springer.com/article/10.1186/s12935-018-0503-5

Abstract Background Abnormal expression of long non-coding RNA (lncRNAs) often facilitates unrestricted growth of cancer cells. Long intergenic non-protein coding RNA 1510, an enhancer lncRNA (LINC01510), a lncRNA enhancer is upregulated in colorectal cancer (CRC), and its expression might relate to MET as revealed by lncRNA microarray data. However, the potential biological role of LINC01510 and its regulatory mechanism in CRC remain unclear. Therefore, we investigated the involvement of LINC01510 in the proliferation of CRC cells. Methods Microarray analysis, In situ hybridization, colony formation assay, MTT assay, Western blotting, quantitative RT-PCR and flow cytometry were applied. The two-tailed Student’s t test and analysis of variance or general linear model of single factor variable was used for statistical analyse. Results In the present study, we found that LINC01510 was significantly upregulated in CRC tissues and cell lines. The LINC01510 expression level were associated with the clinicopathological grade and stage. Meanwhile, gain- and loss-of-function assays demonstrated that LINC01510 overexpression increased CRC cell proliferation, and promoted cell cycle progression from the G1 phase to the S phase. Further study indicated that LINC01510 was positively correlated with the expression of MET, and its effects were most likely at the transcriptional level. Conclusions Taken together, our findings suggested that upregulation of LINC01510 contributes to the proliferation of CRC cells, at least in part, through the regulation of MET protein. LINC01510 could be a candidate prognostic biomarker and a target for new therapies in CRC patients.